This product is analyzed for solubility in DMSO on a lot to lot basis. The specification is: ≥ 20.0 mg/mL. Kindly review the lot specific certificate of analysis for the resulting maximum solubility of the lot received.
SML0800
Rimonabant hydrochloride
≥98% (HPLC), powder, cannabinoid type-I receptor antagonist
Synonyme(s) :
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide hydrochloride, SR-141716, SR-141716A, SR141716, SR141716A
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Sélectionner une taille de conditionnement
5 MG
96.70 CHF
25 MG
392.00 CHF
Sélectionner une taille de conditionnement
Changer de vue
5 MG
96.70 CHF
25 MG
392.00 CHF
About This Item
Formule empirique (notation de Hill) :
C22H21Cl3N4O · HCl
Numéro CAS:
Poids moléculaire :
500.25
Code UNSPSC :
12352200
ID de substance PubChem :
Nomenclature NACRES :
NA.77
Produits recommandés
Nom du produit
Rimonabant hydrochloride, ≥98% (HPLC)
Essai
≥98% (HPLC)
Forme
powder
Conditions de stockage
desiccated
Couleur
white to beige
Solubilité
DMSO: 20 mg/mL, clear
Température de stockage
2-8°C
Chaîne SMILES
CC1=C(C2=CC=C(Cl)C=C2)N(C3=CC=C(Cl)C=C3Cl)N=C1C(NN4CCCCC4)=O.Cl
InChI
1S/C22H21Cl3N4O.ClH/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15;/h5-10,13H,2-4,11-12H2,1H3,(H,27,30);1H
Clé InChI
REOYOKXLUFHOBV-UHFFFAOYSA-N
Informations sur le gène
human ... CNR1(1268)
Application
Rimonabant hydrochloride has been used as an antagonist of cannabinoid 1 (CB1) receptor:
- to study its effects on protein synthesis in C2C12 myotubes[1]
- to analyze its effects on human astroglia[2]
- in combination with methanandamide (mAEA) to study its effects on murine gastric vagal afferent mechanosensitivity[3]
Actions biochimiques/physiologiques
Rimonabant acts as a mycobacterial membrane protein large 3 (MMPL3) inhibitor.[4] Rimonabant hydrochloride exhibits therapeutic activity against weight reduction and smoking cessation.[5]
Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity. Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
Rimonabant hydrochloride (SR-141716A) is a potent and selecvtive CB1 cannabinoid inverse agonist/antagonist with some GPR55 agonist activity and an appetite suppressant.
Caractéristiques et avantages
This compound is featured on the Cannabinoid Receptors and Cannabinoid Receptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Mention d'avertissement
Danger
Mentions de danger
Conseils de prudence
Classification des risques
Acute Tox. 3 Oral - Eye Irrit. 2
Code de la classe de stockage
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
Vous ne trouvez pas la bonne version ?
Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Wei Chen et al.
Naunyn-Schmiedeberg's archives of pharmacology, 386(8), 721-732 (2013-04-27)
Effects of cannabinoid receptor 1 (CB1R) blockade were observed by comparing 9-day and 6-week SR141716 treatments in monosodium glutamate (MSG)-induced hypometabolic and hypothalamic obesity (HO) in rats for the first time and molecular mechanisms were investigated. Compared with normal rats
Marc-Antoine Perrin et al.
Journal of pharmaceutical sciences, 102(7), 2311-2321 (2013-05-23)
Crystalline polymorphism occurs frequently in the solid state of active pharmaceutical ingredients, and this is problematic for the development of a suitable dose form. Rimonabant, an active pharmaceutical ingredient developed by Sanofi and discontinued because of side effects, exhibits dimorphism;
A novel validated RP-HPLC method development for the estimation of rimonabant hydrochloride in bulk and tablet dosage forms
Nama S, et al.
African Journal of Pharmacy and Pharmacology, 5(2), 207-213 (2011)
Jorge Emilio Ortega et al.
European journal of pharmacology, 709(1-3), 13-19 (2013-04-09)
Current pharmacological therapies for depression, including selective serotonin reuptake inhibitors (SSRI), are far from ideal. The cannabinoid system has been implicated in control of mood and neural processing of emotional information, and the modulation of serotonin (5-HT) release in the
Svetlana Slavic et al.
Journal of molecular medicine (Berlin, Germany), 91(7), 811-823 (2013-05-03)
The cannabinoid receptors, CB1 and CB2, are expressed in the heart, but their role under pathological conditions remains controversial. This study examined the effect of CB1 receptor blockade on cardiovascular functions after experimental MI and in experimental metabolic syndrome. MI
Articles
We offer many products related to cannabinoid receptors for your research needs.
-
Hi ! In the product information its marked that rimonabant's solubility in DMSO is "20 mg/mL, clear". Is it its maximum solubility in DMSO?
1 answer-
Helpful?
-
Active Filters
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique
